Requirement for Innate Immunity and CD90(+) NK1.1(−) Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

We sought to define cellular immune mechanisms of synergy between tumor-antigen–targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an antibody targeting tyrosinase-related protein 1 (αTRP1), a nat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Immunol Res
Autores principales: Moskalenko, Marina, Pan, Michael, Fu, Yichun, de Moll, Ellen H., Hashimoto, Daigo, Mortha, Arthur, Leboeuf, Marylene, Jayaraman, Padmini, Bernardo, Sebastian, Sikora, Andrew G., Wolchok, Jedd, Bhardwaj, Nina, Merad, Miriam, Saenger, Yvonne
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4690202/
https://ncbi.nlm.nih.gov/pubmed/25600438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-14-0120
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares